Agios Pharmaceuticals, Inc.
NASDAQ:AGIOBiotechnology
+$0.50 today
- Market cap
- $1.78B
- Beta
- 0.59
- P/E (TTM)
- -4.7
- EPS (TTM)
- -$7.19
Volume 0.60M
Average 1.11M
AGIO Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Agios Pharmaceuticals, Inc.NASDAQ: AGIO
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt remains negative
Q1 FY2026 short-term debt was $18.81M, compared with $0 a year earlier.
Context
- Short-term debt amounted to 1.6% of total assets at the end of Q1 FY2026, up 1.6 pp from a year earlier.
- Short-term debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 18.39M USD
- Year-over-year change
- —
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.39M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Debt vs competitors
How AGIO compares with its peers on the latest reported figures
- AGIO's Mar 2026 short-term debt of $18.81M is the 3rd highest of the 7 companies compared; the peer median is $4.07M.
- Short-term debt amounts to 1.6% of total assets for AGIO, versus a peer median of 0.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $72M | — | — | 5.6% | |
| Jun 2026 | $55.45M | — | +99.1% | 1.7% | |
| Mar 2026 | $18.81M | — | — | 1.6% | |
| Mar 2026 | $8.15M | +78.8% | +44.5% | 1.7% | |
| Jun 2026 | $0 | — | — | 0.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $0 | — | — | 0.0% |
| Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AGIO) | $4.07M | +78.8% | +71.8% | 0.8% | |
Competitors are the stored peer set for AGIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 203.13M | 139.26M | 88.21M | 76.25M | 89.13M |
| Short-term Investments | 816.89M | 643.86M | 688.72M | 817.46M | 765.3M |
| Net Receivables | 4.38M | 2.21M | 2.81M | 4.11M | 10.58M |
| Inventory | 0 | 8.49M | 19.08M | 27.62M | 32.92M |
| Other Current Assets | 0 | 38.96M | 35.02M | 40.17M | 44.13M |
| Total Current Assets | 1.06B | 832.77M | 833.84M | 965.6M | 942.05M |
| Property, Plant & Equipment (Net) | 104.23M | 88.12M | 69.79M | 54.55M | 41.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 266.38M | 313.87M | 29.44M | 638.32M | 310.01M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.9M | 3.96M | 4.06M | 4.72M | 3.93M |
| Total Non-current Assets | 373.51M | 405.95M | 103.28M | 697.6M | 355.17M |
| Total Assets | 1.44B | 1.24B | 937.12M | 1.66B | 1.3B |
| Account Payables | 16.7M | 18.62M | 9.78M | 16.64M | 18.36M |
| Short-term Debt | 0 | 0 | 0 | 0 | 18.39M |
| Tax Payables | 0 | 0 | 0 | 871K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 19.82M | 12.25M | 23.23M | 29.94M | 18.2M |
| Total Current Liabilities | 59.83M | 62.63M | 67.96M | 81.16M | 82.21M |
| Long-term Debt | 0 | 0 | 0 | 0 | 21.82M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 3.28M | 1.16M | 880K | (21.73M) |
| Total Non-current Liabilities | 85.94M | 75.28M | 58.14M | 41.09M | 21.91M |
| Total Liabilities | 145.76M | 137.9M | 126.1M | 122.24M | 104.11M |
| Common Stock | 71K | 71K | 72K | 73K | 75K |
| Retained Earnings | (238.76M) | (470.56M) | (822.65M) | (148.92M) | (561.71M) |
| Accumulated OCI | (1.2M) | (12.54M) | (441K) | (1.52M) | 2.19M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.29B | 1.1B | 811.02M | 1.54B | 1.19B |
| Total Debt | 97.09M | 85.66M | 72M | 56.99M | 62.02M |
| Net Debt | (106.03M) | (53.6M) | (16.21M) | (19.26M) | (27.11M) |
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
Intrinsic Alpha fair value
Locked
Current Price
$29.68
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.